The company expects EPS to be between $4.02 and $4.12. On a non-GAAP basis, EPS is expected to be in the range of $4.75 and $4.85.
NanoString Technologies hopes to use proceeds from the stock offering to support the commercial launch of its Digital Spatial Profiling platform next year.
The company said its product revenues for the year rose 101 percent while its services revenues rose 7 percent.
The company also announced that its Ares Genetics subsidiary has been awarded a €1.6 million grant to develop antibiotic resistance technologies.
Abbott's CFO said he expects mid-single-digit growth from diagnostics in Q1 2018 and mid-to-high single digit growth for the full year.
Companies in the life science tools and molecular diagnostics spaces provided updates on their businesses at the 36th annual JP Morgan Healthcare Conference this week in San Francisco.
Invitae is expecting to net revenues of $59 million in 2017 via its base business, and $67 million in total revenues including acquired companies.
The firm said it expects fourth quarter revenues of $12.3 million to $12.5 million, a year-over-year increase of 13 percent to 15 percent.
The company also expects to report a 31 percent increase in full-year 2017 revenues.
The firm said it completed approximately 176,000 Cologuard tests during the quarter, a 115 percent year-over-year spike.
Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.
The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.
Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.
In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.